Cleveland Clinic Vasculitis Advances and Controversies 2025
A comprehensive Cleveland Clinic vasculitis course focused on the latest advances, controversies, and practical challenges in the diagnosis and treatment of systemic vasculitis, including small vessel vasculitis, large vessel vasculitis, EGPA, giant cell arteritis, ANCA-associated vasculitis, CNS involvement, glucocorticoid management, imaging, pathology, plasma exchange, and tocilizumab use.
Course Details:
Cleveland Clinic Vasculitis Advances and Controversies 2025 includes 22 recorded videos and 18 PDF resources, providing a focused review of current diagnostic and therapeutic strategies for clinicians managing patients with systemic vasculitis.
Focus: Emerging treatment in small vessel vasculitis, emerging treatment in large vessel vasculitis, EGPA management, CNS involvement in vasculitis, challenging vasculitis cases, glucocorticoid use in small and large vessel disease, diagnostic imaging, kidney pathology, large vessel pathology, eye examination in giant cell arteritis, biopsy versus imaging in GCA, plasma exchange in ANCA-associated vasculitis, tocilizumab in GCA, and expert debate-based clinical decision-making.
About This Course
Vasculitis care is complex because diagnosis and treatment often require integration of clinical presentation, imaging, pathology, organ involvement, disease subtype, medication risks, and rapidly evolving evidence.
Cleveland Clinic Vasculitis Advances and Controversies 2025 dives into the complexities and innovations in the treatment and diagnosis of multiple forms of vasculitis. The course reviews emerging treatments, diagnostic controversies, glucocorticoid strategies, CNS involvement, renal pathology, ocular findings, and evidence-based debates that influence real-world patient care.
The program is designed to help clinicians critically appraise new therapies and diagnostic tools while improving confidence in managing small vessel vasculitis, large vessel vasculitis, giant cell arteritis, EGPA, ANCA-associated vasculitis, and complex systemic vasculitis presentations.
Why Choose This Course
- Cleveland Clinic 2025 course dedicated to advances and controversies in vasculitis
- Includes 22 recorded videos and 18 PDF resources
- Reviews treatment advances in both small vessel and large vessel vasculitis
- Includes focused sessions on EGPA, CNS vasculitis, glucocorticoid use, imaging, pathology, and difficult cases
- Features expert debates on biopsy versus imaging in GCA, plasma exchange in ANCA-associated vasculitis, and tocilizumab use in GCA
- Designed for rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, nurse practitioners, nurses, and physician assistants
- Practical clinical format for improving diagnosis, treatment selection, and multidisciplinary vasculitis care
Core Learning Areas
Treatment Advances
Emerging treatment options for small vessel vasculitis, large vessel vasculitis, EGPA, GCA, ANCA-associated vasculitis, and complex systemic disease.
Diagnostic Strategy
Imaging in large vessel vasculitis, kidney pathology, large vessel pathology, eye examination in GCA, and biopsy versus imaging controversies.
Glucocorticoids & Biologics
Current and future glucocorticoid use, tapering considerations, toxicity reduction, tocilizumab in GCA, and evolving biologic strategies.
Complex Cases & Debates
CNS involvement, challenging vasculitis cases, plasma exchange in ANCA-associated vasculitis, expert panel discussions, and real-world controversies.
Complete Curriculum
- Complexities and innovations in vasculitis diagnosis and treatment
- Current evidence across small vessel and large vessel vasculitis
- Integration of clinical findings, imaging, pathology, and therapeutic response
- Practical approach to subtype-specific vasculitis care
- Expert discussion of controversial management questions
- Recorded lectures with supporting PDF materials
- High-yield update for clinicians managing vasculitis patients
- New and emerging therapies for small vessel vasculitis
- Current evidence shaping treatment selection
- Induction and maintenance treatment considerations
- Balancing disease control with medication toxicity
- Clinical implications of recent trials and treatment strategies
- Patient selection for advanced or targeted therapy
- Practical application to real-world rheumatology and internal medicine practice
- New treatment approaches in large vessel vasculitis
- Giant cell arteritis and Takayasu arteritis treatment considerations
- Biologic therapy and steroid-sparing strategies
- Monitoring disease activity and treatment response
- Risk of relapse and long-term management planning
- Clinical controversies in treatment escalation
- Practical strategies for individualized large vessel vasculitis care
- Eosinophilic granulomatosis with polyangiitis clinical overview
- Recognition of EGPA manifestations and disease patterns
- Treatment options and evolving therapy strategies
- Managing asthma, eosinophilia, systemic disease, and organ involvement
- Biologic and targeted therapy considerations
- Long-term monitoring and relapse prevention
- Patient-centered treatment planning for EGPA
- CNS involvement in systemic vasculitis
- Clinical signs and neurologic presentations
- Differential diagnosis and mimics of CNS vasculitis
- Imaging, laboratory, and pathology considerations
- Treatment challenges in neurologic vasculitis
- Risk stratification and multidisciplinary management
- Practical approach to complex CNS vasculitis scenarios
- Expert discussion of challenging vasculitis cases
- Complex diagnostic and management dilemmas
- Clinical reasoning in critically ill vasculitis patients
- Balancing uncertainty, disease severity, and treatment risk
- Use of imaging, pathology, and laboratory data in difficult cases
- Real-world decision-making from experienced faculty
- Practical takeaways for complex vasculitis practice
- Current role of glucocorticoids in small vessel vasculitis
- Balancing efficacy with toxicity reduction
- Glucocorticoid tapering strategies
- Minimizing long-term steroid complications
- Combining glucocorticoids with immunosuppressive or biologic therapy
- Patient-specific factors influencing steroid use
- Future directions in glucocorticoid-sparing care
- Glucocorticoid treatment in giant cell arteritis and large vessel vasculitis
- Initial treatment, tapering, and relapse monitoring
- Role of steroid-sparing agents
- Balancing flare prevention with long-term adverse effects
- Duration of therapy considerations
- Monitoring clinical and imaging response
- Practical approach to glucocorticoid management in large vessel disease
- Advancements in imaging techniques for large vessel vasculitis
- Imaging strategies for diagnosis and disease monitoring
- Role of ultrasound, CT, MRI, PET, and vascular imaging approaches
- Assessing disease activity and structural damage
- Imaging interpretation in treatment response and relapse
- Practical limitations and pitfalls of vascular imaging
- Integration of imaging into multidisciplinary vasculitis care
- Renal involvement in small vessel vasculitis
- Kidney biopsy interpretation and clinicopathologic correlation
- Glomerulonephritis patterns in vasculitis
- Pathology clues that guide diagnosis and severity assessment
- Renal prognosis and treatment implications
- Collaboration between rheumatology, nephrology, and pathology
- Practical approach to vasculitis-related kidney disease
- Pathologic features of large vessel vasculitis
- Temporal artery and large vessel tissue findings
- Histologic patterns in giant cell arteritis and related disorders
- Correlation of pathology with imaging and clinical presentation
- Diagnostic limitations and sampling considerations
- Role of biopsy in modern vasculitis diagnosis
- Practical interpretation of pathology reports in large vessel disease
- Ocular manifestations of giant cell arteritis
- Clinical importance of early eye examination
- Recognizing visual symptoms and urgent warning signs
- Ophthalmologic assessment in suspected GCA
- Preventing vision loss through rapid diagnosis and treatment
- Coordination between rheumatology, ophthalmology, and primary care
- Practical approach to eye-related GCA risk assessment
- Diagnostic modalities in giant cell arteritis
- Role of biopsy in suspected GCA
- Role of imaging in suspected GCA
- Strengths and limitations of each diagnostic approach
- Clinical scenarios where biopsy may be preferred
- Clinical scenarios where imaging may guide decision-making
- Expert debate format to clarify real-world diagnostic choices
- Role of plasma exchange in ANCA-associated vasculitis
- Evidence supporting and questioning PLEX use
- Potential benefit in selected severe presentations
- Renal and pulmonary considerations in severe AAV
- Balancing clinical urgency, evidence, and patient-specific factors
- Practical availability and logistics of plasma exchange
- Expert debate on when PLEX may or may not be appropriate
- Clinical evidence for tocilizumab in giant cell arteritis
- First-line therapy considerations in GCA
- Patient selection for biologic therapy
- Benefits and limitations of tocilizumab use
- Balancing steroid reduction with cost, safety, and relapse risk
- When to consider tocilizumab early in treatment
- Expert debate on universal versus selective biologic use in GCA
- Faculty Q&A across treatment advances
- Discussion of clinical controversies and real-world implementation
- Clarification of diagnostic and therapeutic decision points
- Practical guidance for challenging patient scenarios
- Audience-driven discussion of vasculitis practice questions
- Expert perspectives from rheumatology, nephrology, pathology, and ophthalmology
- Clinically relevant takeaways for day-to-day vasculitis management
Learning Objectives
- Critically appraise emergent treatment options in small vessel vasculitis and large vessel vasculitis
- Evaluate central nervous system involvement in vasculitis
- Assess the current and future landscape of glucocorticoid use in vasculitis management
- Discuss imaging advancements in large vessel vasculitis and other diagnostic modalities in vasculitis
- Appraise diagnostic modalities in giant cell arteritis
- Evaluate the clinical evidence supporting the use of tocilizumab as a first-line therapy in giant cell arteritis
- Appraise the role of plasma exchange in ANCA-associated vasculitis
- Improve diagnostic reasoning using clinical, imaging, ophthalmologic, renal pathology, and large vessel pathology findings
- Recognize treatment controversies and apply evidence-based decision-making to complex vasculitis cases
- Translate expert debate and case-based insights into practical vasculitis patient care
Who Should Take This Course
This course is directed toward rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, nurse practitioners, nurses, and physician assistants interested in the diagnosis and treatment of vasculitis.
It is especially useful for clinicians who manage giant cell arteritis, ANCA-associated vasculitis, EGPA, small vessel vasculitis, large vessel vasculitis, CNS vasculitis, renal vasculitis, ocular complications, and patients requiring advanced imaging, biopsy interpretation, biologics, glucocorticoid-sparing strategies, or multidisciplinary care.
Delivery & Access
22 Videos
Recorded Cleveland Clinic vasculitis sessions covering treatment, diagnosis, imaging, pathology, debates, and case discussions.
18 PDFs
Supporting PDF materials included for structured review, study, and clinical reference.
10.2 GB
Complete recorded course package with video and PDF learning materials.
Support
Course Highlights
Advanced Vasculitis Update
Focused review of current treatment advances in small vessel, large vessel, EGPA, GCA, and ANCA-associated vasculitis.
Diagnostics & Imaging Focus
Covers large vessel imaging, kidney pathology, large vessel pathology, eye exam in GCA, biopsy decisions, and diagnostic controversies.
Expert Debate Format
Includes practical debates on biopsy versus imaging in GCA, plasma exchange in AAV, and tocilizumab use in GCA.
FAQ
Who is this course best suited for?
This course is best suited for rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, nurse practitioners, nurses, and physician assistants interested in vasculitis care.
What is included in this course?
The course includes 22 recorded videos and 18 PDF resources, with a total package size of 10.2 GB.
What topics are covered?
Topics include small vessel vasculitis, large vessel vasculitis, EGPA, CNS involvement, glucocorticoid use, large vessel imaging, kidney pathology, large vessel pathology, eye exam in GCA, biopsy versus imaging in GCA, plasma exchange in ANCA-associated vasculitis, tocilizumab in GCA, and challenging vasculitis cases.
Does this course cover giant cell arteritis?
Yes. The course includes giant cell arteritis diagnosis, eye examination, biopsy versus imaging, large vessel imaging, glucocorticoid use, and tocilizumab therapy debates.
Does this course cover ANCA-associated vasculitis?
Yes. The course includes small vessel vasculitis, kidney pathology, plasma exchange debates, glucocorticoid use, and practical management considerations relevant to ANCA-associated vasculitis.
Is this course case-based?
Yes. The course includes challenging vasculitis case discussions, expert Q&A, and debate-based sessions that address real-world diagnostic and management decisions.
Is this a recorded course?
Yes. This product is provided as recorded course access so you can review the material at your own pace.
Does this course include CME or a certificate?
No. CME credits and certificates are not included with this course package.
Who can I contact for support?
You can contact support at [email protected].
Reviews
There are no reviews yet.